Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.
Paradigm Biopharmaceuticals Ltd. has announced the cancellation of a total of 250,000 shares as part of an employee share scheme buy-back. The cessation of securities, which includes both ordinary fully paid shares and restricted shares, was effective as of April 5, 2024. This strategic move aligns with the company’s efforts to manage its share capital structure.
For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.